Most Read Articles
01 Dec 2019
Macrolide antibiotics are derived from the Streptomycesspecies. These contain either 14-membered (erythromycin [ERM],clarithromycin [CAM], roxithromycin [RXM]), 15-membered(azithromycin [AZM]) or 16-membered (spiramycin, josamycin,midecamycin) macrocyclic lactone rings. They inhibit proteinsynthesis by reversibly binding to the 23S ribosomal RNA (rRNA)in the 50s subunit of the bacterial ribosome. Traditionally,macrolides are used as first-line agents in respiratory, skin,soft tissue, and urogenital infections, and they are also activeagainst gram-positive cocci and atypical pathogens.
29 Nov 2019
Metformin Extended Release 500 mg,750 mg, and 1000 mg
Jairia Dela Cruz, 4 days ago
Nonsmall cell lung cancer (NSCLC) patients harbouring sensitive EGFR mutations may fare well with the third-generation tyrosine kinase inhibitor osimertinib as an upfront therapy, with the results of a network meta-analysis showing that the drug tops other currently available options in terms of progression-free survival and tolerability.
01 Dec 2019
Pneumonia is a common infection– affecting around 3,200 people inSingapore in 2016 – making it the thirdmost common cause of hospitalisation inthe country. Its common complications,especially with delayed or inappropriatetreatment, include bacteraemia andseptic shock, lung abscesses, pleuraleffusions, empyema, pleurisy, respiratoryfailure and renal failure.

Crisaborole 2% ointment proven safe, effective in hidden, genital and facial psoriasis

01 Feb 2020

Patients with intertriginous, anogenital or facial psoriasis see significant clinical improvements with the use of crisaborole 2% ointment, a nonsteroidal phosphodiesterase 4 inhibitor, according to the results of a study. The topical agent is also well tolerated.

To assess the safety and efficacy of crisaborole 2% ointment, a double-blind, randomized, vehicle-controlled trial was performed in 21 participants with intertriginous, anogenital and facial psoriasis. They were randomly assigned 2:1 to receive 4 weeks of twice-daily treatment with either crisaborole 2% ointment (n=14) or vehicle ointment (n=7), which was followed by 4 weeks of open-label treatment with crisaborole 2% ointment. Disease severity was measured using the Target Lesion Severity Scale (TLSS).

After 4 weeks, participants in the crisaborole group showed substantially greater improvement compared with those in the vehicle group (66 percent vs 9 percent; p=0.0011). This improvement persisted through the open-label phase, exhibiting 81-percent lesional improvement by week 8. Moreover, 71 percent of participants in the crisaborole group achieved clinical clearance.

No adverse events were reported.

This finding was consistent with that of a previous study, which suggested that the application of crisaborole ointment to sensitive skin areas was well tolerated in healthy volunteers, making it a potential topical treatment alternative for patients with psoriasis or atopic dermatitis. [Am J Clin Dermatol 2016;17:519-526]

The present study was limited to a single tertiary care centre and by its small sample size, according to the investigators
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
01 Dec 2019
Macrolide antibiotics are derived from the Streptomycesspecies. These contain either 14-membered (erythromycin [ERM],clarithromycin [CAM], roxithromycin [RXM]), 15-membered(azithromycin [AZM]) or 16-membered (spiramycin, josamycin,midecamycin) macrocyclic lactone rings. They inhibit proteinsynthesis by reversibly binding to the 23S ribosomal RNA (rRNA)in the 50s subunit of the bacterial ribosome. Traditionally,macrolides are used as first-line agents in respiratory, skin,soft tissue, and urogenital infections, and they are also activeagainst gram-positive cocci and atypical pathogens.
29 Nov 2019
Metformin Extended Release 500 mg,750 mg, and 1000 mg
Jairia Dela Cruz, 4 days ago
Nonsmall cell lung cancer (NSCLC) patients harbouring sensitive EGFR mutations may fare well with the third-generation tyrosine kinase inhibitor osimertinib as an upfront therapy, with the results of a network meta-analysis showing that the drug tops other currently available options in terms of progression-free survival and tolerability.
01 Dec 2019
Pneumonia is a common infection– affecting around 3,200 people inSingapore in 2016 – making it the thirdmost common cause of hospitalisation inthe country. Its common complications,especially with delayed or inappropriatetreatment, include bacteraemia andseptic shock, lung abscesses, pleuraleffusions, empyema, pleurisy, respiratoryfailure and renal failure.